The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
The patent is titled “Ovarian Cancer Vaccines,” and covers nucleic acid-based delivery of the vaccine. The lead inventor is the late Dr. Vincent Tuohy of Cleveland Clinic.
The ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.
“We are pleased to receive this notice of allowance from the USPTO, providing additional protection for our ovarian cancer vaccine technology, including a possible mRNA vaccine,” Dr. Amit Kumar, chairman and CEO of Anixa, said in a statement.
“Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute, which supports preclinical innovative interventions and biomarkers for cancer prevention and interception,” he added.
